Bristol-Myers Squibb to buy Peninsula heart drug maker for $13.1 billion

An early post-recession bet on precision heart drugs will pay off with a $13.1 billion purchase of Brisbane's MyoKardia Inc. by drug giant Bristol-Myers Squibb Co. The $225-per-share offer by Bristol-Myers Squibb (NYSE: BMY) represents a 61% premium over MyoKardia's stock price when it closed Friday, but it also translates into a big win for a small company (NASDAQ: MYOK), its venture backers and a management team that steadily built its future on a personalized way of treating a silent killer of…

Click to view original post